Josh Nathan-Kazis, Barron's

Josh Nathan-Kazis


Mountain View, CA, United States

Contact Josh

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Barron's
  • Moneyish

Recent articles by Josh:

Covid-19 Death Toll Could More Than Double Before the End of the Year, New Forecast Says

Experts at the IHME now say that they expect another 225,000 Covid-19 deaths in the U.S. before the end of 2020. → Read More

Roche Stock Is Rising Because the Company Has a Covid-19 Antigen Test

The company said Tuesday the test will be available in Europe in late September. → Read More

Investors Are Betting Big on a Covid-19 Vaccine. Is That Safe?

Investors have piled into the stocks of companies working on a Covid-19 vaccine. Here’s how it could play out as these products get ready for prime time. → Read More

President Trump Promised a Vaccine Before the End of the Year. What You Need to Know.

Campaign address skips over the essential question of whether the vaccines will be safe and effective. → Read More

Abbott Shares Climb as U.S. Buys Out Supply of New Covid-19 Test

Abbott appears to have sold the entire 2020 run of the test to the U.S. government. → Read More

AstraZeneca Stocks Gets a Boost From Report of U.S. Fast-Tracking

But the drugmaker says it has had no discussions with the U.S. government about an emergency use authorization. → Read More

Coronavirus Vaccine News Hits the Market. More Is on the Way.

After a bit of a late summer breather, news about a Covid-19 vaccine is heating up again as a handful of leading programs move rapidly into a decisive phase. → Read More

Johnson & Johnson Buys Biotech Momenta Pharmaceuticals for $6.5 Billion

Momenta is the second biotech specializing in immune-mediated diseases snapped up this week → Read More

Novavax Announces Deals to Sell Covid-19 Vaccine in India, Japan, and Low-Income Countries

The agreements follow the release of positive results on the biotech’s vaccine. → Read More

Regeneron’s Covid-19 Antibody Looks Promising in Animal Test

Company scientists posted a paper about a trial of the drug in monkeys and hamsters. → Read More

Regeneron Pharmaceuticals Reports Earnings Tomorrow. Here’s What to Expect.

The call comes as the race for a Covid-19 antibody heats up. → Read More

Glaxo and Sanofi Will Sell 100 Million Covid-19 Vaccine Doses to the U.S. for Less Than $10.50 Each

The deal appears to price the vaccine at less than $10.50 a dose. → Read More

Gilead Shares Sink on Disappointing Earnings

But the drugmaker also increased its earnings guidance for 2020. → Read More

Centene CEO Says Covid-19 Vaccine Profits Should Be Capped for Companies That Took Government Aid

“I think they should be allowed... maybe a 20, 25% margin,” CEO Michael Neidorff tells Barron’s. → Read More

Glaxo and Sanofi to Provide Covid-19 Vaccine to the U.K. ‘We Don’t Expect to Profit.’

A rift is opening between drug companies that say they plan to profit off their vaccines and those that won’t. → Read More

Gilead Reports Earnings Tomorrow. Here’s What to Expect.

This plague year has been good for Gilead Sciences. → Read More

Moderna Is Asking $60 for Covid-19 Vaccine, According to Report, Drawing Criticism From Capitol Hill

The two-dose regimen is well above other known vaccine prices. → Read More

Pfizer CEO Says Companies Should Make Profit On Covid-19 Vaccines

“So far, we are executing meticulously well,” Albert Bourla tells Barron’s. → Read More

Pfizer Stock Jumps on Earnings Beat and Vaccine Progress

The big pharma firm Pfizer announced second-quarter financial results Tuesday morning. → Read More

Moderna Begins Phase 3 Covid-19 Vaccine Study, With Another $472 Million From the Government

The biotech is the first vaccine developer to do so, helped by another $472 million from the government. → Read More